Background: Despite advances in chemotherapy and supportive care, pancreatic ductal adenocarcinoma (PDAC) continues to carry a dismal prognosis, with a five-year survival rate of approximately 13%. While immunotherapy has revolutionized treatment for several malignancies, its efficacy in PDAC remains limited. Recent research has shifted focus toward integrating immunotherapy with chemotherapy, radiation, and targeted therapies in an effort to overcome therapeutic resistance and improve outcomes. Ongoing clinical trials are actively investigating these multimodal strategies. Materials and Methods: A systematic search was conducted using PubMed and ScienceDirect to identify relevant studies published in the past six years. Search terms included “pancreatic adenocarcinoma immunotherapy,” “pancreatic cancer treatments,” and “combination treatments for pancreatic adenocarcinoma.” Only English-language articles were included. Results: A total of 126 articles were initially identified through the database search. After a full-text screening, 48 articles were deemed potentially relevant. Following a rigorous review, 11 studies met the inclusion criteria and were selected for analysis. These studies included randomized controlled trials, non-randomized controlled trials, and retrospective studies. Meta-analyses and case reports were excluded. Articles that failed to meet the inclusion criteria were excluded, primarily due to the absence of relevant data addressing the main objective of this review. Conclusions: Combination strategies with immunotherapy and chemotherapy offer modest survival gains in metastatic settings, yet efforts in resectable and borderline resectable disease have fallen short. These outcomes reflect the profound immunosuppressive forces of the PDAC microenvironment. A new era of treatment must move beyond broad immunotherapeutic applications toward a precision-driven model. Molecular markers, such as KRAS mutations and circulating tumor DNA (ctDNA) profiles, are beginning to illuminate paths for personalized therapy selection. Future progress will depend on biomarker-guided clinical trials, a deeper understanding of immune resistance mechanisms, and bold innovation at the intersection of immunology and tumor biology.
Background: Pancreatic adenocarcinoma (PDAC) is a leading cause of cancer-related mortality due to its aggressive progression and late diagnosis. Despite advances in diagnosis and treatment, survival outcomes remain poor, with a median survival of 5.8 months. Objective: The aim of the study is to evaluate the impact of diagnostic and therapeutic approaches on survival outcomes in patients with pancreatic adenocarcinoma, while also assessing the risk factors for PDAC. Methods: This study is a retrospective analysis of 68 patients with suspected pancreatic tumors who underwent endoscopic ultrasound-guided fine needle aspiration biopsy (EUS-FNAB) between 2019 and 2022 at the Cluj-Napoca County Emergency Clinical Hospital. Patient demographics, risk factors, histopathological results and treatment outcomes were analyzed using statistical methods. Results: Of 68 patients, 35 were diagnosed with PDAC. Modifiable risk factors, such as alcohol and smoking, alongside non-modifiable factors like age and hereditary predisposition, were prominent. Among PDAC patients, 42.8% received palliative chemotherapy, while only 8.6% underwent curative surgical intervention due to advanced disease stages. Median survival varied significantly based on treatment: 2.4 months for untreated patients versus 8.1 months for those receiving oncological or surgical management (p=0.0082). Conclusion: Modifiable and non-modifiable risk factors significantly raise the incidence of pancreatic cancer. Therefore, employing a multidisciplinary approach to detect the disease in its early stages and optimize personalized treatment plans can enhance patient outcomes. At the same time, traditional oncological treatments improve survival and quality of life, but newer approaches, such as immunotherapy combined with conventional radiotherapy, chemotherapy, molecular targeted therapy, and other diverse treatment modalities, have the potential to further extend survival.